Goldman Sachs analyst Corinne Johnson started Structure Therapeutics (GPCR) with an Early-Stage Biotech rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Holds 2025 Annual Shareholders Meeting
- Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
- Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright
- Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating